Valuation: MetaVia Inc.

Market Cap 8.1M 7.21M 6.68M 6.06M 11.38M 768M 11.57M 80.21M 31.51M 402M 30.4M 29.77M 1.28B P/E 2026 *
-0.49x
P/E 2027 * -0.52x
Enterprise Value 8.1M 7.21M 6.68M 6.06M 11.38M 768M 11.57M 80.21M 31.51M 402M 30.4M 29.77M 1.28B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
71.39%
Yield 2026 *
-
Yield 2027 * -
1 day+5.69%
1 week-9.09%
Current month-17.20%
1 month-22.16%
3 months-22.62%
6 months-13.91%
Current year-84.56%
1 week 1.2
Extreme 1.2
1.44
1 month 1.2
Extreme 1.2
1.7
Current year 0.97
Extreme 0.9661
9.61
1 year 0.97
Extreme 0.9661
14.85
3 years 0.97
Extreme 0.9661
74.25
5 years 0.97
Extreme 0.9661
5,618.8
10 years 0.97
Extreme 0.9661
79,200.08
Manager TitleAgeSince
Chief Executive Officer 50 10/08/2023
Director of Finance/CFO 68 26/10/2023
Chief Tech/Sci/R&D Officer - 11/10/2026
Director TitleAgeSince
Director/Board Member 55 30/12/2019
Director/Board Member 76 30/12/2019
Director/Board Member 50 08/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/10/26 Free

Chief Technology Officer

53,000 0.8045%
23/01/26 Free

Chief Executive Officer

32,000 1.3913%
23/01/26 Free

Chief Financial Officer

28,000 1.2174%
Change 5-day change 1-year change 3-year change Capi.($)
+5.69%-9.09%-88.41%-96.64% 8.1M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+10.35%+13.02%+87.74% 51.87B
+6.91%+8.57%+6.88%+72.12% 51.2B
+1.32%+3.03%+26.66%+45.68% 43.76B
+3.13%+9.22%+19.68%+130.79% 42.09B
+6.96%+3.11%+259.75%+594.67% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+5.34%+30.98%+26.07% 22.8B
Average +3.27%-0.60%+38.22%+99.97% 37.58B
Weighted average by Cap. +2.96%+0.62%+50.67%+123.70%

Financials

2026 *2027 *
Net sales - -
Net income -19.62M -17.46M -16.18M -14.66M -27.56M -1.86B -28.02M -194M -76.28M -972M -73.58M -72.05M -3.1B -28.78M -25.62M -23.74M -21.51M -40.43M -2.73B -41.11M -285M -112M -1.43B -108M -106M -4.55B
Net Debt - -
Projected Income Statement - Annual - MetaVia Inc.
Logo MetaVia Inc.
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Employees
8
Date Price Change Volume
20/10/26 US$1.300 +5.69% 15,124
19/10/26 US$1.230 -2.38% 54,277
16/10/26 US$1.260 -8.03% 75,916
15/10/26 US$1.370 +0.74% 50,284
14/10/26 US$1.360 -4.90% 40,626
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - MetaVia Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.230USD
Average target price
19.33USD
Spread / Average Target
+1,471.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MetaVia Inc.
  1. Stock Market
  2. Stocks
  3. MTVA Stock